Ninds preclinical screening platform for pain (pspp)

Active Indefinite Delivery Contract Awarded Last action

Contract number
75N95024D00038
Awardee
Awarding agency
Task orders
1 $36,035,836 obligated

Award facts

Opportunity
Combined order value
  • $36,035,836 Current, with exercised options
  • $65,840,280 Potential, with all options
Last date to order 43% complete
IDV ceiling 45% used
$80,000,000.00
Maximum order
$80,000,000.00
Award type
Single award
Who can order
Only the awarding agency
Funding agency
National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Institute of Neurological Disorders and Stroke awarded an indefinite-delivery contract to Psychogenics Inc., a Total Small Business, with an $80 million ceiling on September 6, 2024. This is a single-award IDIQ. The contract supports the NIH's Helping to End Addiction Long-term (HEAL) initiative and establishes a Preclinical Screening Platform for Pain (PSPP) to evaluate investigational agents for potential non-addictive pain treatments.

Work is performed in Paramus, New Jersey. The IDIQ runs through September 5, 2029, with a five-year ordering period. The originating solicitation, posted April 2, 2024, sought a contractor to conduct in-vitro and in-vivo testing of submitted investigational agents, assessing efficacy, pharmacokinetics, side effects, and abuse liability across pain models and related assays. The relevant NAICS code is 541714 (Research and Development in Biotechnology); the PSC code is AD11 (R&D—Biotechnology).

A $65.84 million delivery order was issued under this IDIQ on September 6, 2024, also carrying the Total Small Business set-aside. The delivery order, priced on a cost-plus-fixed-fee basis, is scheduled for completion September 5, 2029, and covers screening of investigational agents through the PSPP platform. Psychogenics provides preclinical drug discovery and screening services using SmartCube and eCube platforms for in-vitro and in-vivo testing.

Task orders

Transactions

Action Obligated Date
Other Administrative Action P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N95024D00038?

75N95024D00038 was awarded to Psychogenics Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 6, 2024.

How much is contract 75N95024D00038 worth?

Orders under 75N95024D00038 have obligated $36,035,836. Their combined potential value, with all options, is $65,840,280. 75N95024D00038's own ceiling is $80,000,000. A single order can be worth up to $80,000,000.

How many orders have been placed under contract 75N95024D00038?

1 order has been placed under 75N95024D00038, the latest on September 6, 2024.

Which agency awarded contract 75N95024D00038?

National Institute on Drug Abuse (National Institutes of Health) awarded 75N95024D00038, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).

Who can order from contract 75N95024D00038?

75N95024D00038 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract 75N95024D00038 competed?

The extent of competition for 75N95024D00038 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV